Chemed Corp. (CHE, Financial) filed Annual Report for the period ended 2010-12-31.
Chemed Corp. has a market cap of $1.49 billion; its shares were traded at around $65.22 with a P/E ratio of 17.07 and P/S ratio of 1.16. The dividend yield of Chemed Corp. stocks is 0.86%. Chemed Corp. had an annual average earning growth of 20.4% over the past 10 years.Hedge Fund Gurus that owns CHE: Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns CHE: Ron Baron of Baron Funds, Chuck Royce of Royce& Associates, Mario Gabelli of GAMCO Investors, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jeremy Grantham of GMO LLC.
Effective January 1, 1994, the Company acquired all the capital stock of Patient Care, Inc. (Patient Care), for cash payments aggregating $20.6 million, plus 35,000 shares of the Companys Capital Stock. An additional cash payment of $1.0 million was made on March 31, 1996 and another payment of $1.0 million was made on March 31, 1997.
In July 1995, the Companys Omnia Group (formerly Veratex Group) completed the sale of the business and assets of its Veratex Retail division to Henry Schein, Inc. (HSI) for $10 million in cash plus a $4.1 million note for which payment was received in December 1995.
Effective September 30,1997, the Company completed a merger between its 81-percent-owned subsidiary, National Sanitary Supply Company, and a wholly owned subsidiary of Unisource Worldwide, Inc. for $21.00 per share, with total payments of $138.3 million.
Ventures. The cash proceeds to the Company totaled $57.5 million, of which $5.0 million was placed in escrow pending settlement of Patient Cares receivables with third-party payers. Of this amount, $2.5 million was distributed as of October 2003, $1.7 million was distributed as of November 2004 and the remainder was distributed as of October 2006.
Effective February 24, 2004, the Company completed a merger of its wholly owned indirect subsidiary, Marlin Merger Corp., and Vitas Healthcare Corporation. Under the terms of the merger agreement, Vitas stockholders received cash of $30.00 per share. The transaction, including the refinancing of existing Vitas debt and other payments made in connection with the merger, totaled approximately $415 million in cash.
Read the The complete Report
Chemed Corp. has a market cap of $1.49 billion; its shares were traded at around $65.22 with a P/E ratio of 17.07 and P/S ratio of 1.16. The dividend yield of Chemed Corp. stocks is 0.86%. Chemed Corp. had an annual average earning growth of 20.4% over the past 10 years.Hedge Fund Gurus that owns CHE: Steven Cohen of SAC Capital Advisors. Mutual Fund and Other Gurus that owns CHE: Ron Baron of Baron Funds, Chuck Royce of Royce& Associates, Mario Gabelli of GAMCO Investors, Jean-Marie Eveillard of First Eagle Investment Management, LLC, Jeremy Grantham of GMO LLC.
Highlight of Business Operations:
On April 2, 1991, the Company completed the sale of DuBois Chemicals, Inc. (DuBois), a wholly owned subsidiary, to the Diversey Corporation (Diversey), then a subsidiary of The Molson Companies Ltd. Under terms of the sale, Diversey agreed to pay the Company net cash payments aggregating $223.4 million, including deferred payments aggregating $32.4 million.Effective January 1, 1994, the Company acquired all the capital stock of Patient Care, Inc. (Patient Care), for cash payments aggregating $20.6 million, plus 35,000 shares of the Companys Capital Stock. An additional cash payment of $1.0 million was made on March 31, 1996 and another payment of $1.0 million was made on March 31, 1997.
In July 1995, the Companys Omnia Group (formerly Veratex Group) completed the sale of the business and assets of its Veratex Retail division to Henry Schein, Inc. (HSI) for $10 million in cash plus a $4.1 million note for which payment was received in December 1995.
Effective September 30,1997, the Company completed a merger between its 81-percent-owned subsidiary, National Sanitary Supply Company, and a wholly owned subsidiary of Unisource Worldwide, Inc. for $21.00 per share, with total payments of $138.3 million.
Ventures. The cash proceeds to the Company totaled $57.5 million, of which $5.0 million was placed in escrow pending settlement of Patient Cares receivables with third-party payers. Of this amount, $2.5 million was distributed as of October 2003, $1.7 million was distributed as of November 2004 and the remainder was distributed as of October 2006.
Effective February 24, 2004, the Company completed a merger of its wholly owned indirect subsidiary, Marlin Merger Corp., and Vitas Healthcare Corporation. Under the terms of the merger agreement, Vitas stockholders received cash of $30.00 per share. The transaction, including the refinancing of existing Vitas debt and other payments made in connection with the merger, totaled approximately $415 million in cash.
Read the The complete Report
